For four decades, a mutated protein called KRAS drove pancreatic cancer's lethality while resisting every scientific attempt to stop it — earning the grim designation 'undruggable.' Now, a pill called daraxonrasib has done what generations of researchers could not: in a 501-patient international trial, it doubled median survival for metastatic pancreatic cancer patients, reducing mortality risk by 60 percent in a disease where fewer than one in thirty patients survives five years. The breakthrough, born from a 2013 discovery of a hidden flaw in KRAS's molecular surface, signals not merely a ne
Infobae
· May 13, 2026
· health
· 9 min de lectura
High
Verificación: Verificado
Daraxonrasib duplica supervivencia en cáncer de páncreas metastásico
Pancreatic cancer affects over 500,000 people annually with 470,000 deaths globally; five-year survival at stage four is only 3%, making this therapeutic advance potentially life-extending for thousands of patients.
◉
Health & Medicine
2761 artículos relacionados
FDA approves Wegovy for heart disease prevention, expanding blockbuste…
infobae · 99% coincidencia
El ARN mensajero abre camino a vacunas contra 30 enfermedades infeccio…
infobae · 90% coincidencia
WHO endorses GLP-1 weight-loss drugs, issues first clinical guidance a…
El Tiempo · 90% coincidencia
Ozempic: Riesgos crecientes por uso estético sin supervisión médica
Medio digital El Zorro Nortino · 90% coincidencia
Weight-Loss Drugs Show Promise in Reducing Alcohol Cravings, But Clini…
infobae · 90% coincidencia
Cobertura Relacionada
El Mostrador · Aug 20
Estudio chileno identifica huella epigenética de la esquizofrenia en desarrollo temprano
Estudio chileno identifica una huella epigenética resistente en células de pacientes con esquizofrenia, sugiriendo que l…
La Vanguardia · Aug 20 Las secuelas de los trastornos alimentarios persisten décadas después del alta médicaLos trastornos de la conducta alimentaria dejan secuelas físicas que pueden persistir décadas después del alta médica, a…
Clarin.com · Aug 20 Experta en sueño: despertarse de noche es normal, pero evita mirar el relojLa psicóloga Nuria Roure explica que despertarse en la noche es normal, pero mirar el reloj y forzarse a dormir agravan …
Prensa Latina · Aug 20 Nicaragua destaca avances del Cuerpo Médico Militar en su 47 aniversarioEl Cuerpo Médico Militar de Nicaragua conmemoró su 47 aniversario destacando avances en servicios sanitarios y capacidad…
Sesgo y Encuadre
No hay datos de análisis detallado para esta lente. Intenta volver a ejecutar las lentes desde el panel de administración.
Impacto Geopolítico
🌎
Breakthrough pancreatic cancer drug daraxonrasib doubles survival rates, but this is a medical advancement with minimal direct geopolitical implications.
Escalation Risk
low
Confidence
HIGH
Indirect soft power advantage to the United States through biotech innovation leadership; potential healthcare access disparities between developed and developing nations regarding expensive new treatments.
Lente Económico
📈
Daraxonrasib doubles pancreatic cancer survival rates, creating major pharmaceutical breakthrough with significant biotech sector implications and potential healthcare cost shifts.
Market Signal
bullish
Confidence
HIGH
Pharmaceutical/Biotechnology
Healthcare/Medical Services
Medical Devices and Diagnostics
Health Insurance
Oncology Research
Patients with metastatic pancreatic cancer gain access to life-extending treatment, though high costs may create affordability challenges and insurance coverage debates. Families face potential financial burden despite improved survival outcomes.
FDA expedited review likely leads to faster approval and market entry. Healthcare systems must develop reimbursement frameworks and pricing policies. Potential pressure for drug price regulation, insurance coverage mandates, and equitable access programs. May influence oncology research funding priorities.